Seven questions to ask before flying abroad for CAR-T

Key takeaways

• China had eight NMPA-approved CAR-T products by October 2026, seven for blood cancers and one for gastric cancer [1].
• Approval is indication-specific. A product approved for lymphoma is not approved for myeloma, and vice versa [1].
• Treatment is usually two trips with a manufacturing gap of roughly three to four weeks between them [4].
• List prices sit around RMB 1.0–1.3 million per course, which is a fraction of US list prices but still self-paid by most foreign patients [2][6].
• Severe cytokine release syndrome needs intensive care and tocilizumab on site, not a promise of experience [3][5].

Why these questions are worth more than a brochure

CAR-T is a treatment in which the infusion itself is the easy part. Engineered T cells multiply inside the patient over the following days, and the same activation that kills tumour cells can produce fever, hypotension, hypoxia and neurological toxicity. Grading follows the ASTCT consensus, management escalates from supportive care to tocilizumab and corticosteroids, and the severe end of that scale belongs in an intensive care unit [3][5].

Add a border and three things get harder at once: eligibility has to be checked against another country's approvals, the waiting period has to be lived somewhere, and the bill has to be settled in a currency and a system you do not control. The questions below are ordered that way — eligibility, then safety, then money.

The condition in context: what CAR-T does to the body

CAR-T collects a patient's own T cells, engineers them to recognise a surface target, expands them outside the body, and reinfuses them after a short course of lymphodepleting chemotherapy. The target decides which cancers the product can treat: CD19 for B-cell lymphomas and leukaemia, BCMA for myeloma, CLDN18.2 for the single approved gastric product [1][4].

That is why the questions below start with the label rather than the technology. Everything else — the toxicity profile, the length of stay, the price bracket — follows from which target and which product a centre intends to use.

1. Does my disease sit inside an approved indication?

CAR-T is not one drug. Each product carries its own approved indication, and Chinese approvals cover relapsed or refractory large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, multiple myeloma, B-cell acute lymphoblastic leukaemia, and — since 2026 — a CLDN18.2-directed product for gastric cancer [1].

Ask: which product, which approval number, and does my histology, stage and line of prior treatment fall inside its label?

A good answer names the product and quotes the indication. A weak answer is "we treat all cancers" or "we can also do what is not yet approved here". Everything downstream — cost, legal status, insurance — depends on this first answer.

2. Is this commercial treatment or a clinical trial?

These are different documents, different risks and different rights. Commercial treatment means paying for an approved product at an approved dose. A trial means an investigational protocol with eligibility criteria, a sponsor, monitoring, and a defined exit.

Ask: am I signing a treatment consent or a trial consent? Who is the sponsor? What happens to my follow-up if I withdraw?

A good answer distinguishes the two without prompting. A weak answer blurs them, or uses words like "compassionate use" and "expanded access" without naming the framework behind them.

3. Who looks after the four weeks in between?

Treatment is not one admission. In practice it is two, with a gap in the middle while the cells are manufactured. Chinese consensus guidance treats the manufacturing window as two to six weeks, with bridging therapy used to hold the disease steady in higher-risk patients [4].

Ask: where do I stay during the gap, who do I call if I develop a fever, is that period in the quoted price, and who pays if manufacturing fails and the cells have to be collected again?

The gap is where cross-border plans usually break. A centre that has thought about it will have a written answer, a named contact and a price.

4. Can you manage severe cytokine release syndrome on site?

This is the question that separates a treatment offer from a marketing claim. Grade 3 and 4 cytokine release syndrome and immune effector cell-associated neurotoxicity need monitored beds, vasopressors, oxygen, and tocilizumab available without delay [3][5].

Ask: do you have a dedicated intensive care unit? Is tocilizumab stocked in the hospital or ordered in? How many grade 3 or above cases did you manage in the past two years? Which senior physician covers nights?

A good answer describes a structure: beds, a protocol, a named department that takes over. A weak answer describes a feeling: "we have rich experience".

5. What is the legal route for a foreign patient?

China has no medical-visa category. Most patients enter on an S2 private-affairs visa or under a visa-free arrangement, which affects how long they may stay and what they must show at the border [7]. If the treatment falls outside an approved indication, the hospital also has to explain the compliance route it intends to use.

Ask: which visa should I apply for, which documents will you issue, and who handles an extension if my stay runs long?

6. Am I paying upfront or through direct billing?

Foreign patients in China are overwhelmingly self-paying, and fewer than 30% of international insurers can settle directly with a Chinese hospital [6]. Direct billing depends on a contract between that hospital and your insurer — not on how good your policy is.

Ask: do you hold a direct-billing agreement with my insurer? If not, which documents will I need to claim, and who requests pre-authorisation?

For a course of treatment priced in seven figures, this question decides whether the plan is feasible at all.

7. Show me follow-up data, not a count of patients treated

"We have treated thirty international patients" contains almost no information. Response rate, duration of response, median follow-up, relapse rate and severe toxicity rate do.

Ask: how many patients, followed for how long, with what response and what relapse? Can you share de-identified summaries?

A good answer may be modest — "we are a small centre, our follow-up is not mature" is an honest answer and a reasonable one. A weak answer substitutes a patient story for a statistic, or treats "completed treatment" as "achieved remission".

What good and weak answers look like

Availability and limits

• This is an editorial guide to due diligence, not medical advice or a recommendation of any centre [1][3].
• Product counts and indications change; verify the current label before relying on any figure here [1].
• Prices quoted are list prices for the product, not the total cost of a treatment episode [2].
• Eligibility for CAR-T depends on prior lines, organ function and disease control, and is decided by a treating team [3][4].
• We are not a provider and do not book treatment; the questions exist to help you interrogate whoever does [6].

What to ask before booking

Questions patients ask